Sanford C. Bernstein Reiterates $36.00 Price Target for Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) received a $36.00 price target from investment analysts at Sanford C. Bernstein in a research note issued on Wednesday. The brokerage presently has a a “buy” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price target would indicate a potential upside of 10.13% from the stock’s current price.
Other equities research analysts have also recently issued research reports about the company. Jefferies Group set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, August 1st. Piper Jaffray Cos. set a $54.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. BMO Capital Markets restated a “buy” rating and set a $40.00 price objective on shares of Pfizer in a report on Thursday, July 21st. Finally, Vetr cut Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective on the stock. in a report on Tuesday, June 28th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.55.
Pfizer (NYSE:PFE) traded down 0.2004% on Wednesday, reaching $32.6245. The company had a trading volume of 1,307,192 shares. The firm has a 50-day moving average of $33.89 and a 200-day moving average of $34.37. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market capitalization of $197.89 billion, a P/E ratio of 28.9224 and a beta of 0.86.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/sanford-c-bernstein-reiterates-36-00-price-target-for-pfizer-inc-pfe.html
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter last year, the firm earned $0.56 earnings per share. The business’s revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer will post $2.46 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.67%. Pfizer’s dividend payout ratio (DPR) is 95.24%.
A number of institutional investors have recently bought and sold shares of PFE. Nelson Roberts Investment Advisors LLC increased its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC purchased a new position in Pfizer during the second quarter worth approximately $110,000. Tuttle Tactical Management LLC purchased a new position in Pfizer during the second quarter worth approximately $117,000. Gierl Augustine Investment Management Inc increased its position in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares during the period. Finally, Delphi Private Advisors LLC increased its position in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.